Transient increase in platelet counts associated with COVID-19 infection during TPO-RA as the second-line treatment in children with ITP
Description
The thrombopoietin receptor agonists (TPO-RA) were recommended for primary immune thrombocytopenia (ITP) during the pandemic of COVID-19. However, the incidence of thrombocytosis and thrombosis was sporadically reported in the chronic immune
